Tuesday, November 11
9:00 am Workshop Check-In & Networking
R&D Track
9:30 am Understanding the State-of-Play of TIL Therapies Beyond Melanoma
Synopsis
- Evaluating the unique antigenic landscapes and immune responses that hinder the translation of TIL therapies from melanoma to other tumor types
- Discussing innovative approaches to enhance TIL therapy efficacy across different tumor types
- Reviewing recent research and clinical
CMC Track
9:30 am Integrating AI in the Manufacturing & Analytical Development of TIL Therapies
Synopsis
- Exploring how AI can streamline potency assay development and improve analysis of complex manufacturing data
- Addressing challenges in understanding TIL mechanisms of action and their impact on CMC assay design and validation
- Designing data-driven potency assays that reflect clinical benefit, using matrix-based approaches and AI-enhanced modelling
12:30 pm Networking Break
1:30 pm Overcoming Scale-Up Challenges to Ensure Preparation for Commercial Scale
Synopsis
- Overcoming the challenges of scaling manufacturing from a small number of patients in clinical trials to hundreds in commercial settings
- Identifying and addressing bottlenecks in clinical operations to ensure a smooth transition to commercial scale
- Strategies for transitioning from a clinical development focused company to a more commercial entity, ensuring a smooth transition
1:30 pm Enhancing Starting Material Quality for TIL Manufacturing
Synopsis
- Addressing the challenges in accessing and characterizing high-quality starting material for TIL manufacturing
- Improving communication between clinicians and manufacturers to ensure better quality control of starting materials
- Exploring the impact of tumor site and cancer type on the quality of starting materials